Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC
- Conditions
- Non-infected Venous Leg UlcerVenous Leg UlcerVenous InsufficiencyVenous StasisVenous Reflux
- First Posted Date
- 2025-02-06
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- BioStem Technologies
- Target Recruit Count
- 60
- Registration Number
- NCT06811909
- Locations
- 🇺🇸
Site 17, Guntersville, Alabama, United States
🇺🇸Site 2b, Castro Valley, California, United States
🇺🇸Site 19b, Glendale, California, United States
Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AM
- Conditions
- Non-infected Diabetic Foot UlcerDiabetic FootDiabetic WoundNon-ischemic Diabetic Foot UlcerDiabetic Foot Ulcer
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- BioStem Technologies
- Target Recruit Count
- 60
- Registration Number
- NCT06565156
- Locations
- 🇺🇸
Site 17, Guntersville, Alabama, United States
🇺🇸Site 22, Mesa, Arizona, United States
🇺🇸Site 25, Tucson, Arizona, United States
A Prospective Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AC
- Conditions
- Diabetic Foot Ulcer
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- BioStem Technologies
- Target Recruit Count
- 60
- Registration Number
- NCT06511596
- Locations
- 🇺🇸
Site 02, San Francisco, California, United States
🇺🇸Site 04, Sylmar, California, United States
🇺🇸Site 07, Torrance, California, United States
A Controlled Prospective Treatment Study to Evaluate the Efficacy of Vendaje.
- Conditions
- Diabetic Foot Ulcer
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- BioStem Technologies
- Target Recruit Count
- 100
- Registration Number
- NCT06150209
News
BioStem Technologies Completes Enrollment in Diabetic Foot Ulcer Trial Testing Placental-Derived Allograft
BioStem Technologies has completed enrollment of 71 patients in its BR-AC-DFU-101 clinical trial evaluating BioREtain Amnion Chorion allograft versus standard care for non-healing diabetic foot ulcers.
BioStem Technologies Receives Patent Allowances for Novel Fenestrated Placental Allografts
BioStem Technologies received Notice of Allowance from the USPTO for three new patents covering fenestrated human placental allograft designs manufactured using their proprietary BioREtain process.
BioStem Technologies Launches Pivotal Clinical Trial for Vendaje® in Diabetic Foot Ulcer Treatment
BioStem Technologies initiates BR-AM-DFU clinical trial to evaluate Vendaje® against standard of care in treating diabetic foot ulcers, marking a significant advancement in wound care research.
BioStem Technologies Initiates Pivotal Trial of Vendaje® for Diabetic Foot Ulcers
BioStem Technologies has launched a clinical trial (BR-AM-DFU) to evaluate Vendaje® for treating non-healing diabetic foot ulcers (DFUs).
BioStem Technologies' BioREtain Shows Promise in Healing Diabetic Foot Ulcers
A retrospective study published in the *International Wound Journal* highlights the clinical efficacy of BioREtain-processed placental membranes (RE-AC) in treating complex diabetic foot ulcers (DFUs).
BioStem Technologies Initiates Clinical Trial of BR-AC for Diabetic Foot Ulcers
BioStem Technologies has begun the BR-AC-DFU-101 clinical trial to assess BR-AC (BioREtain - Amnion Chorion) for treating non-healing diabetic foot ulcers (DFUs).